insights_auto
Why is DMN down 2,81%?
Dive Deeperchevron_right
DMN:FRA
Diamyd Medical AB
0,069 €
arrow_downward
-2,81%(-0,0020) 1D
5 նոյ, 22:00:00 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for DMN...
Open
0,07 €
High
0,07 €
Low
0,07 €
Mkt. cap
148,01 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
Open
0,07 €
High
0,07 €
Low
0,07 €
Mkt. cap
148,01 մլն
Avg. vol.
0,00
Volume
0,00
52-wk high
1,80 €
52-wk low
0,05 €
No. of employees
42
News stories
From web sources and news partners
CNBC
·
56 րոպե առաջ
Nasdaq sell-off batters Asian chip stocks as SK Hynix, Samsung, Softbank, TSMC tumble
Yahoo Finance
·
55 րոպե առաջ
S&P 500, Nasdaq, Dow Futures Dip As Investors Step Back From AI And Tech With Nasdaq In Correction Territory — NVDA, AAPL, UBER, SOXX In Focus
seMissourian
·
3 րոպե առաջ
Brutal sell-off for AI stocks sends Wall Street reeling, S&P 500 tumbles 4.4%
Fox Business
·
5 ժամ առաջ
Stocks plunge as Dem midterm sweep fuels AI regulatory concerns
Profile
Diamyd Medical AB is a small biotechnology company headquartered in Stockholm, Sweden that focuses on immune modifying therapies for type-1 diabetes. The company's investigational drug retogatein is based on a recombinant form of GAD₆₅, one of two human glutamate decarboxylase gene products.
The company is headquartered in Stockholm, and maintains a "biomanufacturing" facility in Umeå which utilizes bacuolavirus-mediated protein expression. Wikipedia
About Diamyd Medical AB